Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Omeprazole is a small molecule pharmaceutical drug classified as a proton pump inhibitor (PPI). It is used to treat conditions involving excessive stomach acid production such as gastroesophageal reflux disease (GERD), gastric and duodenal ulcers, erosive esophagitis, Zollinger-Ellison syndrome (a rare condition with excess acid due to tumors), and for the eradication of Helicobacter pylori infection in combination with antibiotics. Omeprazole works by irreversibly inhibiting the H+/K+-ATPase enzyme system ("proton pump") on gastric parietal cells—the final step in gastric acid secretion—thereby reducing both basal and stimulated stomach acid output. The drug is available both over-the-counter and by prescription in various oral formulations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on omeprazole.